Laron Syndrome Market

Market Overview:

The 7 major laron syndrome markets reached a value of US$ 2.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.9 Billion by 2034, exhibiting a growth rate (CAGR) of 3.84% during 2024-2034.

The Laron syndrome market has been comprehensively analyzed in IMARC's new report titled "Laron Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Laron syndrome, also known as Laron-type dwarfism or growth hormone insensitivity syndrome (GHIS), refers to a rare genetic disorder characterized by an insensitivity of tissues to growth hormone (GH). The primary symptom associated with the condition is severe short stature, with affected individuals typically exhibiting a height well below the third percentile for their age and sex. Several other common indications include a small head, underdeveloped facial bones, a prominent forehead, a high-pitched voice, etc. Individuals suffering from the ailment may also experience metabolic abnormalities and skeletal issues, such as limb deformities and scoliosis. Additionally, they may exhibit delayed motor development and have a tendency to be overweight due to reduced muscle mass. The diagnosis of Laron syndrome typically involves a comprehensive approach that combines clinical evaluation, biochemical testing, and genetic analysis. Blood tests are utilized to measure insulin-like growth factor-1 (IGF-1) levels, which are commonly found to be low, indicating growth hormone insensitivity. Besides this, genetic testing is also performed to confirm the diagnosis by identifying specific mutations in the growth hormone receptor gene (GHR) or related genes involved in the growth hormone signaling pathway.

The increasing cases of mutations in the growth hormone receptor gene that can lead to dysfunctional or absent growth hormone receptors are primarily driving the Laron syndrome market. Apart from this, the inflating utilization of gene therapy to restore the sensitivity of cells to growth hormone signaling, thereby promoting normal growth and development, is further creating a positive outlook for the market. Moreover, the widespread adoption of recombinant human insulin-like growth factor-1 therapy for increasing growth velocity and improving body composition in patients is also bolstering the market growth. Additionally, various key players are making extensive investments in R&D activities to introduce novel growth hormone analogs that can target alternative pathways or receptors in cells to elicit growth responses independently of the defective growth hormone receptor. This, in turn, is acting as another significant growth-inducing factor. Furthermore, the ongoing advancements in radiological imaging, such as the introduction of bone age assessment that aids in identifying skeletal abnormalities like delayed bone age and alterations in bone structure as well as helps in differentiating the disease from other growth disorders, are expected to drive the Laron syndrome market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Laron syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Laron syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Laron syndrome market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Laron syndrome market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Laron syndrome market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Laron syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the Laron syndrome market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the Laron syndrome market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the Laron syndrome market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of Laron syndrome across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Laron syndrome by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Laron syndrome by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with Laron syndrome across the seven major markets?
• What is the size of the Laron syndrome patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of Laron syndrome?
• What will be the growth rate of patients across the seven major markets?
   

Laron Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Laron syndrome drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Laron syndrome market?
• What are the key regulatory events related to the Laron syndrome market?
• What is the structure of clinical trial landscape by status related to the Laron syndrome market?
• What is the structure of clinical trial landscape by phase related to the Laron syndrome market?
• What is the structure of clinical trial landscape by route of administration related to the Laron syndrome market?